Prioritisation of subgroups for immediate antiretroviral therapy – Authors' reply

Jean Michel Molina, Birgit Grund

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e206
JournalThe Lancet HIV
Issue number5
StatePublished - May 2018

Bibliographical note

Funding Information:
J-MM is an advisory board member of Gilead Sciences, Merck, Janssen, ViiV Healthcare, and Teva, and has received grants from Gilead Sciences and Merck, outside the submitted work. BG reports grants from National Institutes of Health and National Institute of Allergy and Infectious Diseases, during the conduct of the study.

Cite this